In order to evaluate the engraftment of HLA-matching hPBMCs in this new immuno-deficient HLA-humanized mouse model, we transferred 107 HLA-matched (HLA-A2+DR1+) hPBMCs intravenously into HUMAMICE after a total body irradiation and monitored the weight of mice and clinical GvHD signs once a week as described previously[18]. This evidence concerns the gene DR1 and graft versus host disease.